Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate-Reference-Cited by-同舟云学术

Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate

Published:1988-01 Issue:1 Volume:82 Page:69-72
ISSN:0035-9203
Container-title:Transactions of the Royal Society of Tropical Medicine and Hygiene
language:en
Short-container-title:Transactions of the Royal Society of Tropical Medicine and Hygiene

Author:

Chulay J.D.,Fleckenstein L.,Smith D.H.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine,Parasitology

Link

http://academic.oup.com/trstmh/article-pdf/82/1/69/5365765/82-1-69.pdf

Reference12 articles.

1. Antimony in blood,1977

2. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine;Bryceson;Transactions of the Royal Society of Tropical Medicine and Hygiene,1986

3. Urinary excretion of antimony after administration of methyl glucamine antimoniate. Preliminary observations;Chakravarti;Indian Medical Gazette,1950

4. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya;Chulay;Journal of Infectious Diseases,1983

5. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate);Chulay;American Journal of Tropical Medicine and Hygiene,1985

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model;PLOS Neglected Tropical Diseases;2024-04-19

2. The adaptive roles of aneuploidy and polyclonality in Leishmania in response to environmental stress;EMBO reports;2023-07-20

3. Cardiovascular Effects of Environmental Metal Antimony: Redox Dyshomeostasis as the Key Pathogenic Driver;Antioxidants & Redox Signaling;2023-04-01

4. Structure–activity effects in the anti-leishmanial activity of di-alkyl gallium quinolin-8-olates;Dalton Transactions;2023

5. Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs;Biomedical Chromatography;2022-11-04